Edasalonexent - Catabasis Pharmaceuticals

Drug Profile

Edasalonexent - Catabasis Pharmaceuticals

Alternative Names: CAT-1004; Docosahexaenoic acid-sodium salicylate conjugate; Sodium salicylate-docosahexaenoic acid conjugate

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Developer Catabasis Pharmaceuticals; Sarepta Therapeutics
  • Class Anti-inflammatories; Antihyperglycaemics; Docosahexaenoic acids; Non-opioid analgesics; Salicylates; Small molecules
  • Mechanism of Action Inflammation mediator inhibitors; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2018 Updated efficacy data from the open-label extension portion of the phase I/II MoveDMD trial in Duchenne muscular dystrophy released by Catabasis Pharmaceuticals
  • 13 Feb 2018 Efficacy, safety, and pharmacodynamic data from the open-label extension portion of the phase I/II MoveDMD trial in Duchenne muscular dystrophy released by Catabasis Pharmaceuticals
  • 04 Oct 2017 Updated efficacy data from the phase I/II MoveDMD trial in Duchenne Muscular Dystrophy released by Catabasis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top